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ctivating mutations in FGF receptor 3 (FGFR3) cause
several human dwarﬁsm syndromes by affecting
both chondrocyte proliferation and differentiation.
Using microarray and biochemical analyses of FGF-treated
rat chondrosarcoma chondrocytes, we show that FGF inhibits
chondrocyte proliferation by initiating multiple pathways
that result in the induction of antiproliferative functions
and the down-regulation of growth-promoting molecules.
The initiation of growth arrest is characterized by the rapid
dephosphorylation of the retinoblastoma protein (pRb)
p107 and repression of a subset of E2F target genes by a
A
 
mechanism that is independent of cyclin E–Cdk inhibition.
In contrast, hypophosphorylation of pRb and p130 occur
after growth arrest is ﬁrst detected, and may contribute to
its maintenance. Importantly, we also ﬁnd a number of
gene expression changes indicating that FGF promotes many
aspects of hypertrophic differentiation, a notion supported
by in situ analysis of developing growth plates from mice
expressing an activated form of FGFR3. Thus, FGF may
coordinate the onset of differentiation with chondrocyte
growth arrest in the developing growth plate.
 
Introduction
 
Development of most skeletal elements occurs through the
multistep process of endochondral ossification in which a
cartilage template is converted into bone. The formation of
the cartilage template involves mesenchymal condensation
and chondrogenic differentiation. Reserve zone chondrocytes
transit through maturational stages of proliferation, prehyper-
trophy, and hypertrophy within the epiphyseal growth plate,
and eventually undergo apoptosis as the hypertrophic zone
becomes invaded by blood vessels and osteoprogenitor cells,
leading to the formation of trabecular bone.
The extent of longitudinal bone growth depends on the
rates of chondrocyte proliferation and maturation, which are
in turn controlled and coordinated by extensive cell–ECM
interactions and a host of signaling networks elicited by
FGFs, insulin, PTHrP, Indian hedgehog (Ihh), and BMPs,
 
among others (Olsen et al., 2000; Wagner and Karsenty, 2001;
Karsenty and Wagner, 2002). A key role for FGF signaling
was made apparent by the discovery that gain of function
mutations within FGF receptor 3 (FGFR3)* cause several
forms of human dwarfism including achondroplasia, hypo-
chondroplasia, and thanathophoric dysplasia, which are all
characterized by the reduced growth of long bones (Ornitz
and Marie, 2002). Subsequent works in tissue culture and in
mouse models of both gain and loss of function mutations
in FGFR3 indicated that FGF signaling restrains chondrocyte
proliferation and possibly differentiation by direct action on
chondrocytes, as well as by indirect mechanisms (Ornitz and
Marie, 2002). However, the notion that FGF signaling inhibits
chondrocyte differentiation has recently been challenged by
Minina et al. (2002).
The growth arrest exhibited by chondrocytes is in stark
contrast to the typical stimulatory response to FGF exhibited
by most other cell types, and appears to result from a unique
downstream response of proliferating chondrocytes to FGF
rather than a novel signaling property of FGFR3 (Wang et
al., 2001). In vivo analyses have shown increased expression of
STAT proteins, p21, and Ink family Cdk inhibitors (CDKIs)
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in response to excessive FGF signaling, whereas other reports
have demonstrated that FGF-mediated inhibition requires
STAT1 function, both in vitro and in vivo (Chen et al.,
1999; Li et al., 1999; Sahni et al., 1999, 2001; Aikawa et al.,
2001). However, neither p21- nor STAT1-null mice exhibit
overt skeletal abnormalities (Brugarolas et al., 1995; Durbin
et al., 1996). Analyses of mice in which genes for members
of the pRb family had been inactivated showed that the ab-
sence of both p107 and p130 impaired endochondral bone
development by causing excessive proliferation and de-
creased differentiation of growth plate chondrocytes (Co-
brinik et al., 1996; Rossi et al., 2002). In line with this ob-
servation, we established that FGF-mediated growth arrest
of chondrocytes requires functional p107 and p130 pro-
teins, but not retinoblastoma protein (pRb), and that FGF
treatment of cultured chondrocytes causes the hypophos-
phorylation of all three pRbs (Laplantine et al., 2002). Al-
though p107 appears to play the major role, p130 is also re-
quired for maximum growth inhibition (Laplantine et al.,
2002). Together, these observations suggest that STAT1
mediates some aspects of FGF signaling, but that FGF may
use additional components to affect chondrocyte prolifera-
tion and/or differentiation.
To gain further insight into the mechanisms by which
FGF signaling affects these processes, we have used genome
wide expression profiling to elucidate the cascades of gene
expression after FGF treatment of a cultured rat chondro-
sarcoma (RCS) chondrocytic cell line. Our results support a
model in which FGF inhibition of the chondrocyte cell cy-
cle is achieved through the activation of multiple pathways
that act via a “two step” mechanism: (1) direct signaling to
negatively regulate the activities or transcription of key cell
cycle components and mediators of signals that stimulate
chondrocyte proliferation (“initiation of growth arrest”);
and (2) Cdk inhibition and the eventual transcriptional
down-regulation of additional cell cycle protein genes (“main-
tenance of growth arrest”). We also find dramatic changes in
expression of many genes associated with chondrocyte dif-
ferentiation, consistent with the notion that FGF initiates
several aspects of hypertrophic differentiation. These data
have been supported by in situ analyses of growth plates
from mice harboring an activated FGFR3. Together, these
results portray several mechanisms by which excessive FGF
signaling contributes to growth plate pathologies, but also
provide suggestions regarding the role of FGF in normal
bone development.
 
Results
 
The kinetics of FGF-induced cell cycle arrest in RCS cells
 
The RCS cell line exhibits many properties of proliferating
chondrocytes, including the expression of collagen II and
FGFR3 (Mukhopadhyay et al., 1995). Previous work has
shown that treatment of RCS cells with FGF1 causes an in-
hibition of cell cycle progression (Sahni et al., 1999). To
correlate gene expression changes with the kinetics of this
growth arrest, we performed a FACScan™ analysis of RCS
cells at various intervals after treatment with FGF1 and
heparin in the presence of 10% serum. 3 and 6 h of FGF
treatment caused an initial increase in the number of cells
in G2, consistent with previous reports (Aikawa et al.,
2001; Rozenblatt-Rosen et al., 2002; Fig. 1 A). Because of
the G2 block, the percentage of cells in G1 declined relative
to the untreated samples at 3 h as the G1 cells proceeded to
S phase, indicating that most of the cells were not yet
blocked in G1. However, by 6 h of treatment, cells from
G1 were no longer entering the S phase. Thus, the G1
block was first clearly manifest by 6 h after FGF addition.
By 9 h, the G2 block had been relieved and cells continued
to accumulate in G1. These results demonstrate that FGF
treatment of RCS cells causes a transient G2 block that is
evident by 3 h but relieved by 6–9 h, and a sustained G1
block first clearly evident after 6 h of FGF treatment. For
comparison, we used the osteoblastic cell line ROS 17/2.8,
whose proliferation was not inhibited by FGF (Fig. 1 B),
despite the fact that they also harbor functional FGFR3
(Mansukhani et al., 2000).
 
Overview of the gene expression profile of 
FGF-treated RCS
 
RNA was prepared from RCS cells after 1, 3, 6, 10, and 24 h
treatment with FGF1 and heparin or with heparin only. To
identify changes in gene expression that required new pro-
tein synthesis, RNA was also prepared from cells treated
with FGF in the presence of cycloheximide. To assist in the
identification of genes that might be relevant to FGF-
induced growth arrest in RCS cells, RNA was prepared at
the same time points from FGF-treated ROS cells. After
conversion into biotinylated cRNA, the samples were hy-
Figure 1. FACScan™ analysis of RCS and ROS cells in response to 
FGF treatment. Growing cultures were treated with 5 ng/ml FGF1 
and 10 mg/ml heparin for the indicated times and subjected to flow 
cytometry. UN indicates RCS (A) or ROS (B) cells treated with heparin 
only. Numbers on the y axis indicate percentage of total cells 
analyzed per sample.T
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bridized to DNA oligonucleotide microarrays representing
8,799 rat cDNAs and ESTs. No significant change was ob-
served in the expression of RNAs derived from the heparin-
treated control cultures. In contrast, the expression of many
genes was either induced (280) or repressed (697) by greater
than threefold during the course of FGF treatment.
To correlate the regulation of specific gene subsets with
changes in the cell cycle, the genes were grouped according
to their expression patterns using hierarchical clustering to
create the dendrogram shown in Fig. 2, and these patterns
were classified as representative of “early response genes,”
“mid-response genes,” or “late response genes.” A partial list
of the genes contained in these subgroups is presented in Ta-
ble I. The gene array results were verified using Northern
analysis of a selection of genes (Fig. 3).
 
Early response genes
 
This group represents genes exhibiting changes in expression
between 0–3 h after FGF addition, and thus preceding or
coinciding with G2 arrest. (Table I; Fig. 2, E subgroups). In-
cluded within this group are genes for many transcription
factors that are classically defined as “immediate early pro-
teins,” such as members of the AP-1 complex (c-jun, Jun B,
c-fos), ets1, ATF 3, and Egr-1 (not depicted). As expected,
the induction of most of these genes was not inhibited by cy-
cloheximide. Although many of these genes were also in-
duced in ROS cells, the induction was generally less robust
and/or occurred with distinct kinetics from that in RCS
(e.g., Fra-1).
The expression of several genes that would be expected to
have a distinct bearing on the cell cycle was specifically al-
Figure 2. Gene expression profiles after FGF treatment of RCS cells. RNA samples prepared from RCS cells after 0, 1, 3, 6, 10, or 24 h of 
FGF treatment were converted into biotinylated cRNAs and hybridized to rat microarrays (Affymetrix). Genes up-regulated (A) or down-regulated 
(B) by greater than threefold with respect to untreated control samples were subjected to hierarchical clustering as detailed in Materials and 
methods. Average expression is defined by the GeneSpring
® software (Silicon Genetics) and assigned a value of 1, whereas values greater or 
less than this value are visualized as more intense shades of red or green, respectively. Individual genes are represented in rows from left to 
right, and their relative expression level is depicted according to the colorimetric scale at each time point indicated above the dendrograms. 
Major patterns within the dendrograms were determined for selected nodes and are displayed to the right of each dendrogram. By relating 
each of these expression profiles to changes in the cell cycle as defined by the FACScan™ analysis, genes within these subgroups were 
defined as early (E), mid-(M), or late (L) response genes.T
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Table I. 
 
Compilation of genes regulated by FGF treatment of RCS cells and comparison with their expression in ROS cells 
RCS ROS
 1 3 6 10 24 1 3 6 10 24
GenBank/EMBL/DDBJ 
accession no. 
CHX
Early response genes
Transcription
 
 
Krox-24 U75397
 
119 85 50 14
 
-    #
 
31 16 9.3
 
2.6 0.2
krox20 U78102 
 
17 11 22 15 8.8 14 6.3
 
2.4 2.3 0.8
HES-1 D13417
 
7.2
 
1.6 - - -    C 1.8 1.7 2.1 2.6 1.5
Fra-1 M19651
 
111 336 187 66
 
- 1.8
 
3.9
 
3.1 2.7 0.8
fra-2 U18982 1.4
 
3.2
 
2.2 - - 1 0.5 0.7 0.8 1
c-fos X06769
 
8.2
 
1.6 - - -
 
6.3
 
0.6 0.5 0.7 1.1
v-jun homologue AA945867
 
4.6 3.4
 
- 1.6 - 1.2 0.7 1 0.6 0.5
c-jun X17163
 
4 3.7 3.9
 
2.9 - 1.4 0.6 1.2 0.7 0.8
Jun B AA891041
 
18 8.4 10
 
--
 
3.1
 
2.2 2.3 1.3 1.9
GADD153 U30186
 
5.1 3.6
 
1.4 1 0.9 1.1 0.8 0.6 0.7
 
3.3
 
ATF 3 M63282
 
13 2.8
 
0.7 0.9 1.5 2.1 1.1 0.7 0.7
 
3.4
 
Ets-1 L20681 1.1
 
3.8
 
2.6 1.3 -    # 1 1.6 2.7 1 0.8
Dlx-3 D31734 0.3 - - - 0.3 0.7 0.4 0.4 0.5 0.9
 
Signal transduction
 
MKP-1 S74351
 
71 8.4 3.3
 
- - 1.8 0.2 0.3 0.4 1
MKP-3 U42627 
 
6 105 111 100
 
-    C
 
15 34 27 27
 
0.5
uPAR-1 X71898  2.8
 
6.7 4.9 4.1 3.1
 
   #
 
3.9 3.9
 
2.8 2 0.9
PTHrPR AB012944 0.7 0.3 0.1 0.2 0.7 0.4 0.5 0.3 0.3 0.6
fzd L02529 0.7 - -  0.3 0.9 0.9 0.3 0.5 0.5 0.7
ERK1 M61177 0.9 0.6 0.2 0.4 1.2    # 0.9 0.8 1.1 1 1
P38 MAPK AI171630 0.8 0.1 0.2  - 0.3    C 0.8 0.4 0.7 0.6 0.9
IRS-1 X58375 0.4 0.1 0.1  - 0.2    C 0.9 0.3 0.3 0.3 0.5
 
Cell cycle
 
PC3 M60921
 
25
 
2.1 0.8  - -
 
4.9
 
2.1 1.3 0.4 0.8
p21 U24174 2.1
 
3.3
 
1.3 0.8 - 1.4 2 2.3 1.3 1.3
GADD45 L32591
 
4.3 3
 
2.8 1.8 -    # 0.7 0.5 0.9 1 2.5
Pold1 AJ222691 0.8 - -  - - 0.9 0.6 0.8 0.7 0.8
Pola2 AJ011606 0.9 0.3 0.5 0.4 0.5 0.9 0.5 0.6 0.9 1
Id 1 L23148 0.4 - - 0.2 - 0.5 0.3 1.2 2.3 2.2
Id 2 AI230256 0.5 - - - 0.1 1.8 0.3 0.8 1.6 1.3
Id 3 AF000942 0.4 - - - - 1.2 0.7 1.1 1.6 1.8
 
Mid-response genes
Transcription
 
 
HMG I (Y) X62875 1.3
 
3.7 3.7 3.8 3.1
 
   C 0.7
 
4.7 10 10 12
 
Hnf3b L09647 0.8
 
4.4 7.4 4.8
 
1.9    C - - - - -
 
Signal transduction
 
Jag 1  AA900503 1.4
 
3.1 4.2
 
2.9 1.6    C 1.4 1.6 1.5 12 0.9
Ephrin A1  AA892417 1.4
 
4 9.5 6.7 5.7
 
   C 1.2 0.7 0.9 1 1.2
BMP3b D49494 0.8 0.5 - - 0.2  -----
 
Cell cycle
 
p16/Ink4 S79760 1.2
 
2.8 3.3 3.6
 
- - - - - -
Cyclin D1 D14014 1.2
 
6.9 14 14 5.9
 
   C 0.9 1.3 1.2 1.6 1.1
 
Differentiation-related
 
DEC1/bhlh2 AF009330 2.1
 
3.2 3.2
 
2.8 2.2    # 1.1 1.5 1.6 1 1.1
MMP13 M60616 1.9
 
35 74 108
 
-    C 0.5 1.3 0.5 0.6 0.6
OPG U94330 1.2
 
3.2 4.1 3.7
 
1.6    C 1.4 1.1 0.6 0.8 0.8
TIMP-1 AI169327 -
 
184 321 377 999
 
   C 1 1.5 1.1 1.4 1.1
OPN M14656 1.3
 
12 23 31 214
 
   C 1 2.1 2.8
 
3.2 3.3
Late response genes
Transcription
 
 
STAT5a1 U24175 - - - -
 
4.2
 
   # - - - - -
c-Myc Y00396 1.4 1.2 1 0.2 0.3    # 2.3
 
3.2 3.6
 
2.4 1.1T
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tered in RCS cells during the early response stage (Table I).
For example, the gene for PC3, a member of the tob family
that is thought to play an antiproliferative role (Tirone,
2001), was strongly induced during the first hour of FGF
treatment. We also noted the down-regulation of gene ex-
pression of two DNA polymerase (Pol) subunits that oc-
curred as a direct result of FGF signaling because it was also
observed in the presence of cycloheximide. The genes for
p21 and GADD45 were also specifically induced in RCS
cells. Because both p21 and GADD45 can inhibit cyclin/
Cdk activities (Sherr and Roberts, 1999; Zhan et al., 1999;
Vairapandi et al., 2002), their induction may contribute to
the transient G2 arrest of RCS cells seen by 3 h.
An additional feature of the early response of RCS cells to
FGF was the immediate and precipitous decline in expres-
sion of all three Id protein mRNAs (Table I). The Id pro-
teins act as dominant-negative transcriptional inhibitors of
bHLH factors (Yokota and Mori, 2002), and can also pro-
mote cell proliferation by antagonizing the activities or ex-
pression of key cell cycle regulators including pRbs and the
CDKIs p21 and Ink4a/p16 (Yokota and Mori, 2002). In ad-
dition, we noted the down-regulation of several other genes
that play a role in chondrocyte proliferation, including the
signal transduction components PTHrP receptor, Wnt re-
ceptor (frizzled), and the insulin receptor substrate IRS-1
(Table I). Together, analysis of the early response genes re-
 
Signal transduction
 
FGFR-1 D12498 1 1.4
 
3.1 3.6
 
2.4    C 1.1 0.7 1.4 1.6 1.2
ERK3  M64301 1.1 0.9 0.8 1 -    C 1 0.9 1.2 0.9 1
 
Cell cycle
 
Cyclin E D14015 1 0.9 0.7 0.3 0.4    # 0.8 0.8 0.9 1 0.7
Cyclin B1  AA998164 1.1 0.9 1.2 0.7 -    # 0.9 0.8 0.9 0.8 1.1
Cdk2-alpha D28753 0.9 0.8 0.7 - -    # 0.6 0.5 0.7 1 1.1
Cdk2-beta D28754 1 0.6 0.5 - -    # 0.9 0.4 0.8 - 0.8
p55cdc AF052695 0.9 0.6 0.9 0.6 -    # 0.8 0.8 0.7 0.8 1.1
cdc2 AB005540 0.9 1.5 1 0.8 -    # 0.7 1.6 1.8 0.8 1.1
CDC5 AF000578 1 0.8 0.5 0.5 0.3    C 0.7 0.7 0.8 0.9 1
CDC25B D16237 0.9 1 1 0.9 0.3    # 1 0.8 1 0.8 1.2
CAK1 X83579 1.2 1.3 1.7 0.5 -    # 1 0.9 1 1 0.9
Dpola3 AJ011607 0.9 0.6 0.6 0.3 0.2    C 0.9 0.8 0.7 0.8 0.8
Dpola4 AJ011608 1 1 0.6 0.3 0.2    C 0.9 0.8 1 0.9 1.1
Dpola1 AJ011605 0.8 0.7 0.5 0.1 -    C 0.8 0.4 0.8 0.6 1.1
PCNA M24604 1.2 1.4 0.9 0.4 0.3    # 1.2 1 1 1 1
Tyms  L12138 0.9 0.8 0.7 - -    C 0.9 0.8 0.8 0.8 1
dUTPase U64030 0.9 0.9 0.7 0.6 0.1    C 0.9 0.8 0.9 0.7 0.9
PTTG  U73030 1.2 1 0.9 1.1 -    # 0.9 1 0.9 0.8 1.1
TOP2A AA899854 1 1.1 1.1 0.4 -    # 0.9 0.8 0.9 0.7 0.9
MSH2 X93591 0.8 0.8 1 0.3 0.3    # 0.7 0.6 0.7 0.7 1.1
ODC J04791 0.9 1 0.9 0.5 -    # 1.1 1 1.1 1.2 1.1
 
Differentiation-related
 
Annexin V D42137 0.9 1.7 1.8
 
3 3.4
 
   C 1 1.4 1.2 1 1
Annexin II AA946503 -
 
4.1 12 16 3.4
 
   C - - - - -
Chad AF004953 0.7 0.7 0.6 0.8
 
6
 
   # - - - - -
TIMP-2 S72594 1.1 1.1 1.2 0.7
 
3.1
 
   # 1 0.7 0.8 0.9 0.8
SGP-1 S81353 1.1 1.2 1.4 1.7
 
4.1
 
   # 0.8 0.7 0.9 1.2 1
Placement of genes into the early, mid-, or late response list was based on the clustering analysis of Fig. 2 as explained in the text. 1, 3, 6, 10, and 24 at the
top of the columns indicate hours of FGF treatment. Numbers represent fold induction as compared with the expression of each gene in untreated cells.
Induction or down-regulation of expression by threefold or greater is shown as boldface or underlined, respectively. Dashes indicate no expression. Data
obtained from analysis of RCS cells treated with FGF in the presence of cycloheximide are summarized in the column CHX, where C indicates expression
changes inhibited by cycloheximide, and blank spaces depict those unaffected by cycloheximide; # indicates data that were ambiguous because
cycloheximide itself altered the mRNA level or because the change in gene expression occurred after 6 h of the cycloheximide experiment. MKP, map kinase
phosphatase; uPAR, urinary plasminogen activator; PTHrPR, parathyroid hormone–related peptide receptor; fzd, frizzled; IRS, insulin receptor substrate;
Pold, DNA polymerase; Jag, jagged; TIMP, tissue inhibitor of metalloproteinase.
Table I. 
 
Compilation of genes regulated by FGF treatment of RCS cells and comparison with their expression in ROS cells (Continued)
Figure 3. Confirmation of the microarray results using Northern 
analysis. RNA was isolated from RCS cells treated with FGF for the 
indicated times and subjected to Northern analysis using radiolabeled 
probes for PC3, osteopontin (OPN), or osteoprotegerin (OPG) as 
described in Materials and methods.T
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veals specific expression patterns of transcription factors and
signaling molecules that already distinguish RCS and ROS
cell responses to FGF, including the activation of genes en-
coding antiproliferative functions (GADD45, PC3, p21,
and jun B), and the dramatic down-regulation of several
growth-promoting signaling molecules.
 
Mid-response genes
 
Genes in this group exhibit a significant change in expres-
sion between 3 and 6 h after FGF treatment, and thus pre-
cede or coincide with the G1 arrest observed at 6 h (Table I;
Fig. 2, subgroup M). Most notable among these with regard
to cell cycle regulation was induction of the Ink4a/p16 gene.
p16 is an inhibitor of the G1 cyclin D–Cdk complex and an
important mediator of cell cycle arrest (Sherr and Roberts,
1999). Induction of the p16 gene was not inhibited by cy-
cloheximide, was not observed in ROS cells, and was sus-
tained through 10 h of FGF treatment (Table I), consistent
with the notion that p16 also plays a role in the FGF-medi-
ated growth arrest of RCS cells. Paradoxically, we also noted
a strong and sustained induction of cyclin D1 mRNA. Al-
though cyclin D1 induction is usually associated with mito-
genic responses, it has also been observed before the FGF- or
NGF-induced differentiation of growth-arrested neuronal
PC12 cells (Yan and Ziff, 1995).
In addition to changes in expression of these cell cycle reg-
ulators, we also noted a dramatic increase in the expression
of several genes normally elevated in differentiated hyper-
trophic chondrocytes. These include DEC1 (Shen et al.,
2002), osteopontin (OPN), and several genes encoding
components or modifiers of the ECM such as those for
the  collagen matrix metalloproteinase 13 (MMP13) and
TIMP-1. Thus, in the mid-response stage, the cells became
arrested in G1 and the expression of molecules typical of dif-
ferentiated chondrocytes was induced.
 
Late response genes
 
Late response genes exhibited significant changes in expres-
sion just before or during 10–24 h after FGF treatment,
when the cells continue to accumulate in G1 (Fig. 1). These
genes included those within subgroup L in Fig. 2 as well as
genes down-regulated only at 24 h and not included in the
Figure 4. E2F target genes are down-regulated in RCS cells in response to FGF. The expression profiles of rat homologues of previously 
identified human E2F target genes (Ren et al., 2002) were subjected to k-means clustering as detailed in Materials and methods. Each line 
within the graphs represents the relative expression profile for one of the genes listed.T
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dendrogram. Notably, we observed a nearly universal down-
regulation in the expression of many major cell cycle regula-
tors, including that of cyclins E and B1, Cdk2, cdc2, CDC5,
CDC25B, and CAK1 (Table I). Furthermore, several com-
ponents of DNA synthesis were down-regulated, including
ODC, additional DNA polymerase subunits, and PCNA.
Importantly, these changes occurred exclusively in the FGF-
treated RCS samples and were not observed in either un-
treated RCS cells or in ROS cells. These results indicate that
transcription of many of the components of the cell cycle ma-
chinery had become essentially shut down by 10–24 h, and
may represent a mechanism for cell cycle arrest that is distinct
from (or a consequence of) that observed at 6 h after FGF ad-
dition. In addition to the continued production of the ECM
molecules initiated during the mid-response stage, we also
noted the induction of mRNAs for several fibronectin iso-
forms, the cell surface protein CD14, annexin V, TIMP-2,
sulphated glycoprotein-1, dynamin-1, and chondroadherin
at these later time points (Table I and unpublished data).
 
Expression of E2F target genes in response to 
FGF signaling
 
Previous reports have underscored an essential role for the
Rb-related p107 and p130 proteins in chondrocyte growth
arrest and bone development (Cobrinik et al., 1996; Rossi et
al., 2002). These pRbs become hypophosphorylated after
FGF treatment of RCS cells (Laplantine et al., 2002). Hypo-
phosphorylated pRbs mediate growth arrest primarily by
binding E2F transcription factors, leading to either the un-
availability of free, activating E2F1–3 factors and/or the re-
cruitment of transcriptionally repressive p107– or p130–
E2F4/5 complexes to E2F target genes (Trimarchi and Lees,
2002). Using a combination of chromatin immunoprecipita-
tion and microarray technology, a number of putative hu-
man E2F target genes have been identified whose transcrip-
tion is repressed in serum-starved fibroblasts (Ren et al.,
2002). These genes include a number of essential compo-
nents of cell cycle regulation, and DNA synthesis and repair.
We analyzed the expression of some of these E2F target genes
in RCS cells to ascertain whether we could correlate pRb/
p107/p130 hypophosphorylation with down-regulation of
E2F target genes, and whether repression of these genes oc-
curred before or subsequent to the G1 arrest. As shown in
Fig. 4, the majority of these genes were down-regulated with
either relatively rapid (sets 1 or 2) or delayed (sets 4 and 5) ki-
netics, whereas a few genes exhibited no change in their
mRNA levels (set 3) after FGF treatment. Notably, none of
these genes was significantly induced with the exception of
the early, transient activation of c-jun, and none were down-
regulated in FGF-treated ROS cells (unpublished data).
Genes within sets 1 and 2 comprised genes included in the
early or mid-response genes (Table I), and therefore were
down-regulated before G1 arrest. These included Id3 (set 1)
and the DNA polymerase subunits 
 
 
 
 and 
 
 
 
 II (set 2). Impor-
tantly, the down-regulation of several of the E2F target genes
in these groups was observed in the presence of cyclohexim-
ide. In contrast, most of the mRNAs within sets 4 and 5 de-
clined after the G1 arrest at 6 h. and their down-regulation
was sensitive to cycloheximide (Fig. 4; Table I). Thus, tran-
scriptional repression of the E2F target genes in sets 1 and 2
occurred before, and not as a consequence of, G1 arrest,
probably while cells were still traversing the S phase. These
results are consistent with the established central role of
the p107/p130 proteins in chondrocyte growth arrest and
strongly implicate a repression of a subset of critical E2F tar-
get genes in the initiation of growth arrest by FGF.
 
The Rb family proteins exhibit distinct kinetics 
of dephosphorylation
 
Western analysis showed that proliferating RCS cells con-
tained predominantly hyperphosphorylated forms of pRb and
Figure 5. Hypophosphorylation of the pRbs occurs with different 
kinetics and by distinct mechanisms in response to FGF. (A) Kinetics 
of p107, p130, and pRb dephosphorylation. Total protein lysates 
were prepared from RCS cells at the times of FGF treatment indicated 
and subjected to Western analysis using the antibodies indicated. 
Bars to the left of the image depict the position of the hyperphos-
phorylated (top) or hypophosphorylated (bottom) forms of each 
protein. (B) RCS cells were treated with FGF in the presence or 
absence of actinomycin D, and whole-cell extracts were subjected 
to Western analysis using p107 or pRb antibodies. Samples derived 
from cells treated with FGF (fgf), acinomycin D (act), or both (fgf act) 
are indicated above the lanes. (C) Western analysis of p21 expression. 
Protein extracts from FGF-treated RCS cells were subjected to 
Western analysis using anti-p21 antibody. (D) Kinetics of cyclin E–Cdk 
inhibition and association with p21. Cyclin E–Cdk2 complexes 
were immunoprecipitated from protein extracts of RCS cells after 
treatment with FGF for the times indicated. Kinase activity was 
assessed in vitro in the presence of  [
32P]ATP and histone H1 
substrate as detailed in Materials and methods. The remainder of the 
immunoprecipitate was used for Western analysis using antibodies 
against Cdk2 or p21.T
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p130 and a mixture of hyper- and hypo-phosphorylated p107
proteins (Fig. 5 A). On FGF treatment, p107 underwent
rapid dephosphorylation within the first hour. In contrast,
the hypophosphorylated form of pRb predominated only af-
ter 8 h, and those of p130 were first observed after 16 h of
FGF treatment (Fig. 5 A). These distinct kinetics indicated
that the hypophosphorylated forms of the pRbs may be gen-
erated by different mechanisms. Therefore, dephosphoryla-
tion of p107 and pRb by FGF was compared in the presence
or absence of the transcription inhibitor actinomycin D. Hy-
pophosphorylated p107 was still observed when the cells were
treated with FGF in the presence of actinomycin (Fig. 5 B) or
cycloheximide (unpublished data), indicating that this pro-
cess does not require new gene transcription or protein syn-
thesis. In contrast, actinomycin abolished the ability of FGF
to cause the hypophosphorylation of pRb. Together, these
observations are consistent with the notion that dephosphory-
lation of p107 is regulated directly and rapidly by FGF signal-
ing, whereas that of pRb (and p130, unpublished data) occurs
later and requires the induction of gene transcription.
 
Hypophosphorylation of pRb and p130 (but not p107) 
correlates with the inhibition of cyclin E–Cdk2 activity
 
In the normal cell cycle, phosphorylation of the pRbs is me-
diated by the G1 cyclin D–Cdk4/6 and cyclin E–Cdk2
complexes. Harbour and Dean (2000) and Aikawa et al.
(2001) previously showed that cyclin E–Cdk2 (but not cy-
clin D–Cdk) activity is inactivated by p21 after 12 h of FGF
treatment of RCS cells. However, the FGF-induced dephos-
phorylation of p107 that we observed in the presence of ac-
tinomycin occurred independently of p21 (or p16) gene in-
duction (Table I and unpublished data), suggesting that
p107 dephosphorylation does not result from inhibition of
cyclin E–Cdk2.
To test this hypothesis, we analyzed the kinase activity of
the cyclin E–Cdk2 complex and its association with p21 in
RCS cells treated with FGF for 1, 3, 6, and 12 h. Western
analysis indicated that the p21 protein was induced by 2 h af-
ter FGF treatment, consistent with the microarray data of Ta-
ble I, and remained relatively high during the 12 h examined
(Fig. 5 C). However, an in vitro kinase assay of cyclin
E–Cdk2 complexes that had been immunoprecipitated from
protein extracts of FGF-treated RCS cells showed that the ki-
nase activity remained robust during the first 6 h, and was
only clearly inhibited 12 h after FGF addition (Fig. 5 D). The
inhibition of kinase activity correlated with a clear increase in
the association of p21 with the cyclin–Cdk2 complex at 12 h
(Fig. 5 D). Thus, the dephosphorylation of p107 caused
by FGF treatment occurs in the presence of active cyclin
E–Cdk2, and is observed before the induction of p21 and
p21-mediated inhibition of cyclin E–Cdk2. These observa-
tions are consistent with the notion that FGF activates a sig-
naling pathway that acts directly to dephosphorylate p107,
leading to the assembly of p107–E2F complexes and the early
repression of a subset of E2F target genes, to initiate growth
arrest. In contrast, detection of the hypophosphorylated
forms of pRb and p130 correlates with the kinetics of cyclin
E–Cdk2 inhibition, and thus may result from p21-mediated
inhibition of cyclin E–Cdk2 several hours after FGF addition.
 
FGF signaling promotes chondrocyte differentiation
 
In addition to negative regulation of the chondrocyte cell
cycle, FGF signaling exerts a profound affect on the matura-
tion of the growth plate. In contrast to the generally held in-
terpretation that FGF inhibits chondrocyte differentiation,
we have observed changes in the expression of a number of
genes that are more consistent with the opposing view that
FGF promotes at least some aspects of hypertrophic differ-
entiation (Table II). These include the induction of genes
previously reported to be associated with hypertrophic
differentiation such as MMP13, OPN, osteoprotegerin
(OPG), annexin V, and FGFR1, and the down-regulation
of the PTHrP receptor (Deng et al., 1996; Minina et al.,
2002). Although the expression pattern of the Id proteins
has not been previously analyzed in the growth plate, their
down-regulation is also a general feature of many differenti-
ation programs (Norton et al., 1998). In contrast, we did
not observe induction of expression of collagen X, the classi-
cal marker of terminally differentiated chondrocytes. This is
not due to a peculiarity of the RCS cell line because we were
also unable to detect collagen X gene induction in FGF-
treated primary chondrocyte cultures by RT-PCR, even
though induction of MMP13 and OPN could be observed
(unpublished data). These data are consistent with the no-
tion that FGF promotes several (but not all) aspects of hy-
pertrophic differentiation.
In situ analysis was used to assess the expression of sev-
eral of the genes presented in Table II in bone sections de-
rived from P15 wild-type mice or those derived from
mice homozygous for an activating mutation in FGFR3
(Gly369Cys). These mutant mice have been shown to have
a chondrodysplastic phenotype with shorter long bones,
disorganization of the growth plate, and reduced chondro-
cyte proliferation that is associated with increased expres-
sion of STAT proteins p16 and p19 (Chen et al., 1999). In
situ hybridization was performed using 
 
35
 
S-labeled anti-
sense RNA probes corresponding to the collagen X, Id1,
Id3, OPN, or Ihh genes (Fig. 6). In wild-type growth
plates, Ihh expression was detected predominantly in prehy-
 
Table II. 
 
Gene expression changes associated with
chondrocyte differentiation
Gene product Growth plate in vivo
 
a
 
 
(hypertrophic chondrocytes)
FGF-treated RCS
 
PTHrP receptor Down Down
DEC1 Up Up
MMP13 Up Up
OPG Up Up
OPN Up Up
FGFR1 Up Up
ColX Up NC
ColII Down NC
Id1 Down Down
Id2 NT Down
Id3 Down Down
TIMP-1 Up Up
Annexin V Up Up
 
a
 
Data derived from Fig. 6 or literature cited within the text.
NC, no change; NT, not tested.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
 
 
FGF pathways to chondrocyte growth arrest |
 
 Dailey et al. 1061
 
pertrophic chondrocytes, consistent with previous reports
(Karsenty and Wagner, 2002). Expression of collagen X was,
as expected, restricted to hypertrophic chondrocytes that
could be observed near the trabecular bone and at the pe-
riphery of the secondary center of ossification. OPN expres-
sion was also detected in the hypertrophic cells, although its
expression appeared stronger in and around the secondary
centers of ossification and at the bone front, reflecting its
additional expression by osteoblasts. The expression of Id1
and Id3 was particularly interesting because their mRNAs
were detected only in proliferating chondrocytes and in
newly formed bone (presumably by osteoblasts), but were
completely absent in the resting and hypertrophic chondro-
cyte populations (Fig. 6).
Growth plates from the tibia of P15 mice homozygous for
the activating FGFR3 mutation (369/369) exhibit a dis-
torted V shape with a relative scarcity of hypertrophic chon-
drocytes at the bone front and poorly organized secondary
centers of ossification (Chen et al., 1999). Ihh expression in
these mutant growth plates was weak, as has been previously
observed in similar mouse models of unregulated FGF sig-
naling (Fig. 6; Karsenty and Wagner, 2002). Expression of
OPN was strongly induced in the narrow band of hyper-
trophic chondrocytes as well as in osteoblasts in the mutant
growth plate compared with its expression in the wild-type
mouse. Id1 and Id3 expression were reduced in the prolifer-
ating chondrocytes of the mutant growth plate compared
with that observed in the wild type, and most of their ex-
Figure 6. In situ hybridization. Tibia sections from P15 wild-type (WT; A–D and I–L) or FGFR3 mutant (369/369; E–H and M–P) mice were 
stained with Alcian blue, hemotoxylin, and eosin (A and E). R, P, and H depict the regions of the reserve, proliferative, and hypertrophic 
zones, respectively; B indicates trabecular bone and sco the secondary center of ossification. Sections were hybridized with 
35S-labeled RNA 
probes for collagen X (ColX; B and F), Indian hedgehog (Ihh; C and G), Id-3 (D and H), Id-1 (J and N), or osteopontin (Opn; L and P) and 
visualized using darkfield microscopy. After hybridization, sections in J, L, N, and P were stained with hemotoxylin to more precisely localize 
the regions expressing Id-1 and Opn (I, K, M, and O). Arrows indicate chondrocytes expressing OPN.T
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pression was detected only in osteoblasts of the trabecular
bone. Collagen X appears weaker than that in the wild-type
growth plate, although this decrease is likely due to the de-
crease in the number of hypertrophic cells expressing this
marker, rather than, per se, a decrease in collagen X expres-
sion. Indeed, several cells expressing collagen X could be de-
tected around the secondary centers of ossification in some-
what ectopic locations.
Together, these observations show that FGF causes
changes in the expression pattern of several genes in RCS
cells that are similar to those occurring during chondrocyte
differentiation in vivo. Furthermore, the altered expression
of these genes in the growth plates of mice harboring an acti-
vating mutation of FGFR3 mimics the changes observed in
FGF-treated RCS cells, consistent with the notion that ex-
cessive FGF signaling may promote premature differentia-
tion of chondrocytes in the mutant growth plates. However,
the observation that collagen X expression is not induced by
FGF signaling in either cultured or growth plate chondro-
cytes suggests that FGF does not promote all aspects of the
differentiation program.
 
Discussion
 
Genetic studies of several forms of human dwarfism and
mouse models of chondrodysplasic syndromes have estab-
lished that FGF signaling plays a central role in normal bone
growth by regulating both chondrocyte proliferation and
differentiation in the epiphyseal growth plate. The develop-
mental pathology caused by excessive FGF signaling as well
as the unique, negative growth response of chondrocytes to
FGF have prompted several studies to identify the intracel-
lular effectors of FGF signaling in these cells. Although sev-
eral individual molecules have been implicated in the FGF
response, we sought to create a framework in which to ex-
tend these previous observations by documenting the global
patterns of gene expression changes occurring over a 24-h
period in a chondrocytic cell line in response to FGF, and by
correlating these changes with alterations of the cell cycle.
Our results, as discussed in the following paragraphs, are
consistent with a model in which FGF signaling initiates an
interlocking network of signaling and transcriptional events
that act in a concerted and synergistic fashion to impact on
chondrocyte proliferation and differentiation.
 
Multiple pathways contribute to growth arrest in 
response to FGF
 
The cell cycle is controlled by both positive and negative fac-
tors that ultimately determine the activity of the E2F family
of transcription factors. Free E2Fs activate transcription of
a host of target genes, many of which are critical to cell cy-
cle progression, whereas E2Fs bound to hypophosphory-
lated Rb family members mediate transcriptional repression
(Sherr and Roberts, 1999; Trimarchi and Lees, 2002). Be-
cause both p107 and p130 are essential for FGF-mediated
growth arrest of chondrocytes (Laplantine et al., 2002),
much of the focus of the present work was to determine the
molecular events initiated by FGF that lead to p107 and
p130 hypophosphorylation.
 
Initiation of growth arrest
 
FACScan™ analysis showed that RCS cells begin to arrest in
the G1 phase by 6 h of FGF treatment (Fig. 1). In accordance
with our previous works underscoring an important role for
p107 and p130 proteins in this process (Laplantine et al.,
2002), our gene expression data show that a subset of E2F
target genes are rapidly down-regulated before growth arrest
(Fig. 4). We further determined that p107 is the only Rb
family member that is hypophosphorylated at very early times
(Fig. 5), and thus the dephosphorylation of p107 and the re-
pression of a subset of E2F target genes is likely to be the first
key event leading to FGF-mediated growth arrest of RCS
cells. It is unlikely that the dephosphorylation of p107 is due
to changes in composition of the cyclin–Cdk complexes be-
cause we do not observe a down-regulation of gene expression
for any of the components of the cyclin–Cdk machinery (cy-
clins B, D, and E, p55cdc, CDC5, CDC25B, CAK1, Cdk2;
Table I), before growth arrest. In fact, the only change noted
is the induction of cyclin D1 expression (Table I).
Our results also indicate that p107 hypophosphorylation
does not result from the inhibition of cyclin E–Cdk activity.
The microarray data show rapid induction of the CDKI p21
mRNA at 1 h and p16/Ink4a slightly later at 3 h (Table I).
p21 binds both cylinE–Cdk2 and cyclin D–Cdk complexes,
but only inhibits the kinase activity of the former (Sherr and
Roberts 1999). In agreement with Aikawa et al. (2001), we
have observed inhibition of cyclin E–Cdk2 activity as well as
an increased association of p21 with the complex after 12 h
of FGF treatment. However, we did not observe significant
inhibition of cyclin E–Cdk2 or its association with p21 dur-
ing the first 6 h of FGF treatment. Furthermore, the rapid
dephosphorylation of p107 occurs even in the presence of
actinomycin or cycloheximide, and thus ought not to rely
on the synthesis of new products such as p21 (or p16). Al-
though we did not directly assess cyclin D–Cdk function,
our observation that the pRb and p130 proteins remain
phosphorylated during the first 6 h of FGF treatment and
that phosphorylation of these proteins by cyclin E complex
is thought to be dependent on prior phosphorylation by cy-
clin D–Cdk (Harbour and Dean, 2000) are consistent with
sustained cyclin D–Cdk activity during this period.
Together, these data illustrate a mechanism of p107-E2F–
mediated transcriptional repression and growth arrest that
directly result from FGF signaling. This interpretation is
based on the observation that neither the dephosphorylation
of p107 nor the repression of several of the E2F target genes
requires new protein synthesis, and that these events occur
independently of Cdk inhibition. As we have previously pro-
posed (Laplantine et al., 2002), FGF signaling may activate
a phosphatase or the association of a phosphatase with p107,
a possibility that is currently under investigation. Clearly,
the direct signaling mechanism for p107 dephosphorylation
and the initiation of growth arrest elucidated here is distinct
from that of growth arrest resulting from serum withdrawal
and Cdk inhibition, and is a defining feature of the response
of chondrocytes to FGF.
In addition to its role in binding E2Fs and repressing E2F
target gene transcription, hypophosphorylated p107 has
been shown to interact with, and negatively regulate the ac-T
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tivity of, several additional cellular factors including cyclin
E–Cdk and c-Myc (Beijersbergen et al., 1994; Gu et al.,
1994; Zhu et al., 1995). Because c-Myc activity is generally
believed to regulate transcription of genes involved in
growth control and is required for cell cycle progression
(Grandori et al., 2000), interaction of hypophosphorylated
p107 with c-Myc could also affect the expression of this ad-
ditional set of target genes. We have noted changes in the
expression of c-Myc target genes (Grandori and Eisenman,
1997), such as the down-regulation of Id2 and the induction
of p21, that are consistent with the inhibition of myc activ-
ity (Table I and unpublished observations).
 
Maintenance of growth arrest
 
In contrast to the kinetics of p107 dephosphorylation, the
appearance of underphosphorylated forms of pRb and p130
coincide with cyclin E–Cdk2 inhibition and depends on the
activation of new gene transcription, presumably of a CDKI.
Furthermore, Cdk inhibition and hypophosphorylated pRb
and p130 proteins are observed after growth arrest had been
initiated, presumably by p107, and therefore are unlikely to
play a role in the early stages of this process. Although p107
plays a dominant role in growth inhibition of FGF-treated
chondrocyte micromass or organ cultures, p130 is also re-
quired to elicit maximal levels of growth arrest (Laplantine
et al., 2002). In addition, p107
 
 
 
/
 
 
 
 mice exhibit a subtle
bone phenotype compared with the severe chondrodysplasia
manifest in p107
 
 
 
/
 
 
 
;p130
 
 
 
/
 
  mice (Cobrinik et al.,
1996). Thus, p130 may contribute unique functions not
shared by p107 and/or may sustain the growth arrest at later
stages in the FGF response.
Unlike the initiation of growth arrest, establishment of the
maintenance phase relies on the earlier induction of new
proteins such as the CDKIs. As a corollary to the CDKI-medi-
ated Cdk inhibition that characterizes the maintenance
phase, the early elimination of Id protein expression (Table
I) is likely to be an additional essential aspect of the response
of RCS cells to FGF. The Id proteins act as dominant-nega-
tive repressors of bHLH transcription factors and have been
shown to antagonize the expression of both p21 and p16
(Yokota and Mori, 2002). Negative regulation of CDKI ex-
pression by Id proteins is further demonstrated in vivo by
the observations that Id1 / ;Id3 /  neuroblasts exit pre-
maturely from the cell cycle and show elevated levels of p16
and p27 (Lyden et al., 1999). In addition, Lasorella and col-
leagues (Lasorella et al., 2000) have demonstrated that Id2
can bind the hypophosphorylated form of all three pRbs, a
property that appears to interfere with pRb–mediated cell
cycle arrest. Thus, the immediate down-regulation of all
three Id protein mRNAs after FGF treatment of RCS cells
Figure 7. Model depicting the multiple pathways induced in response to FGF treatment of RCS cells leading to cell cycle arrest and initiation 
of differentiation. The initiation of growth arrest encompasses gene expression changes and signaling events observed during the early and 
mid-response stages. The major pathways serve to down-regulate growth-promoting functions and activate antiproliferative functions as 
discussed in the text. These events converge to establish the maintenance of growth arrest, which is characterized by cyclin E–Cdk inhibition, 
the hypophosphorylation of all three pRbs, further down-regulation of E2F target genes and genes encoding other cell cycle components, and 
the induction of genes associated with hypertrophic differentiation during the mid- and late response stages.T
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would play a role in the induction of the p21 and p16
CDKIs, as well as in the repression of E2F target gene tran-
scription by pRb–E2F complexes.
Additional pathways contributing to cell cycle arrest
Repression of E2F target genes were observed with very differ-
ent kinetics, with some down-regulated within 1 h and others
after 10 h of FGF treatment (Fig. 5), despite the fact that
p107 dephosphorylation is so rapid. One possibility is that the
p107–E2F4/5 complex does in fact mediate the repression of
all these genes in response to FGF, but that a longer half-life
of some of the mRNAs masks the transcriptional shutoff.
However, an additional possibility is suggested by a recent re-
port showing that TGF- –mediated transcriptional repres-
sion of the c-Myc promoter, an E2F target gene, requires the
collaboration of p107–E2F complexes with Smad proteins
(Chen et al., 2002). Thus, although the p107–E2F complex
mediates gene repression, it may require additional DNA-
binding cofactors to do so. The observation that down-regula-
tion of some of our E2F target genes requires new protein syn-
thesis could reflect the induction of such cofactors that are not
expressed in RCS cells in the absence of FGF signaling. An
additional mechanism by which FGF promotes growth arrest
may rely on the inhibition of the expression of growth-stimu-
lating molecules such as PTHrP receptor and IRS-1.
Together, these observations show that FGF treatment
leads to a cascade of interlocking events that converge to in-
hibit chondrocyte proliferation, as summarized in Fig. 7. A
perspective that allows for the induction of multiple path-
ways, as opposed to a linear series of events, offers an expla-
nation for the observations that mice containing gene
knockout of individual components of these pathways, such
as STAT1, p21, p107, or p130, do not exhibit severe skele-
tal phenotypes because one or more pathways may be able to
compensate for the loss of another.
FGF signaling initiates chondrocyte differentiation
Chondrocyte proliferation and differentiation in developing
long bones has been shown to be regulated by a number of
signaling molecules, most notably Ihh, PTHrP, BMPs,
IGFs, and FGFs. Although it is well established that Ihh
and PTHrP function in a negative feedback loop to pro-
mote chondrocyte proliferation and restrain differentiation,
(Olsen et al., 2000; Wagner and Karsenty, 2001; Karsenty
and Wagner, 2002), the identification of positive differenti-
ation signals has been more elusive. A number of reports (for
review see Ornitz and Marie, 2002) have suggested that FGF
signaling inhibits chondrocyte differentiation. However, this
is seemingly at odds with the general notion that growth ar-
rest is a prerequisite of, or coordinated with, terminal differ-
entiation. Indeed, our microarray analysis demonstrates that
FGF modulates the expression of a number of genes in RCS
cells (Table II) in a manner that is consistent with the view
that FGF promotes, rather than inhibits, many aspects of
chondrocyte hypertrophic differentiation. This conclusion
was supported by in situ analysis in which the modulation of
expression of several of these genes was determined in epi-
physeal growth plates from wild-type mice as well as mice
harboring an activating FGFR3 mutation. In addition to the
gene expression changes of many differentiation markers we
have identified (Table II), it is worth mentioning that down-
regulation of FGFR3 expression, another feature of chon-
drocyte differentiation, has been previously observed in
FGF-treated RCS cells (Rozenblatt-Rosen et al., 2002).
A recent report by Minina and colleagues (Minina et al.,
2002), in which interactions among the FGF-, Ihh/PTHrP-,
and BMP-signaling pathways were assessed for their effects
on organ cultures of growth plate chondrocytes, also pre-
sented compelling evidence that FGF promotes hypertrophic
differentiation. Their model suggests that FGF promotes
both the onset of differentiation, through the down-regula-
tion of the Ihh/PTHrP pathway, and an acceleration of the
differentiation process in an Ihh/PTHrP-independent man-
ner. The down-regulation of PTHrP (and Ihh) gene expres-
sion that we observe is consistent with Minina’s identifica-
tion of the onset of hypertrophic differentiation (Minina et
al., 2002). In addition, because we have used a tissue culture
system in which chondrocytes are removed from the complex
signaling environment of the growth plate, the majority of
gene expression changes we observe should occur indepen-
dently of the Ihh/PTHrP pathway, and may represent those
contributing to the acceleration of differentiation observed
by Minina et al. (2002). Together, these observations sup-
port the notion that FGF induces many aspects of chondro-
cyte differentiation and indicate that the phenotype of FGF-
induced chondrodysplasias could result from both decreased
proliferation and premature differentiation of growth plate
chondrocytes. Indeed, another feature of FGF-induced chon-
drodysplasias, increased chondrocyte apoptosis, also supports
this view because high levels of apoptosis are characteristic of
terminally differentiated chondrocytes (Sahni et al., 2001).
In conclusion, our observations support the notion that
FGF signaling plays two major, related roles in the epiphy-
seal growth plate by causing the growth arrest of proliferat-
ing chondrocytes, and subsequently, initiating a program of
hypertrophic differentiation. Thus, FGF would serve as a
coordinator that links these two processes and synchronizes
the activities of the different chondrocyte populations. Ob-
viously, these functions of FGF are also subject to control by
other signaling pathways that would influence the onset of
these events. Our observation that expression of collagen X
is not induced also suggests that additional signals are re-
quired to achieve the full terminally differentiated state.
Thus, by coordinating growth arrest and onset of the differ-
entiation program, FGF initiates a switch in the state of pro-
liferating chondrocytes toward hypertrophy.
Materials and methods
Cell culture
Monolayer cultures of the RCS and ROS 17/2.8 osteosarcoma cells were
maintained in DME and 10% FCS. Where indicated, FGF1 and heparin
were added to growing cultures to final concentrations of 5 ng/ml and 5
ug/ml, respectively. In experiments using 20 ug/ml cycloheximide or 1 ug/
ml actinomycin D, the inhibitors were added 15 min before FGF/heparin
addition. Cells were prepared and analyzed for FACScan™ analysis as de-
scribed previously (Laplantine et al., 2002).
RNA isolation and microarray analysis
Total RNA was isolated using TRIzol
® (GIBCO BRL). 3–4 independent
samples were prepared from FGF-treated RCS cells at each time point. Du-T
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plicate RNA samples were prepared from control RCS cultures and FGF
and control samples of ROS cells. Duplicate samples were also prepared
from RCS cells treated with cycloheximide for 0, 1, 3, or 6 h in the pres-
ence or absence of FGF. Biotinylated cRNA was prepared according to the
protocols as detailed (Affymetrix, Inc.) and submitted to the Columbia
University Microarray Facility (New York, NY) for hybridization to the
RGU34A rat genome array and scanning using the GeneArray
® scanner
(Affymetrix, Inc.).
Data analysis
Each U34A chip contains oligonucleotide sequences corresponding to
8,799 rat mRNAs or ESTs. Initial analysis was performed using Microarray
Suite 5.0 software (Affymetrix, inc.). Metrics files were downloaded into
GeneSpring
® software (Silicon Genetics) for all further manipulations. Nor-
malization across all of the chips was performed by using the 50th percen-
tile of all measurements as a positive control. Each measurement for each
sample was divided by this value. The lower 10th percentile was used as a
test for correct background subtraction (“per chip normalization”). The me-
dian of each gene’s expression value over all of the samples was used as a
synthetic positive for each gene and divided into all measurements for that
gene (“per gene normalization”). The values for multiple samples of each
time point were averaged and used for all further analyses. Genes that did
not exhibit a minimum raw signal of 100 in at least one sample in the time
course were filtered out, eliminating most nonexpressed genes. Genes in-
duced or down-regulated by at least threefold were identified by compari-
son of the expression level in each FGF-treated sample with that in the un-
treated (heparin only) control sample and combined using Venn Diagrams
to yield the final lists of “all up-regulated” and “all down-regulated.” These
gene lists were each used to construct the dendrograms of Fig. 2 using
Pearson correlation. Gene subgroups encompassed within nodes along the
tree were selected and subject to the “major expression analysis” function
of the GeneSpring
® program to generate the expression patterns accompa-
nying the dendrograms of Fig. 2. Genes within these subgroups were hand
selected to create Table I. Fold change calculations shown in Table I used
the time 0 (heparin only) value for each cell line as its baseline reference.
For E2F target gene analysis, rat homologues of the human E2F target
genes reported by Ren et al. (2002) were identified using UniGene (Na-
tional Center for Biotechnology Information, Bethesda, MD), and were
subjected to k-means clustering (standard correlation) according to their
expression patterns in FGF-treated RCS cells. Genes not expressed at any
of the time points were excluded from the analysis.
Northern analysis
32P-radio labeled probe for PC3 was prepared from the excised cDNA in-
sert of pBabe PuroPC3 provided by F. Tirone (Instituto di Neurobiologia
CNR, Rome, Italy). DNA fragments of OPN and OPG were generated us-
ing RT-PCR of RNA from FGF-treated RCS cells and primers as follows:
OPN-F, 5 -GTGTCCTCTGAAGAAACGGA-3 ; OPN-R, 5 -CTCGGCA-
CTATCGATCGCAT-3 ; OPG-F, 5 -CCTCCTGCTAATTCAGAAAG-3 ;
OPG-R, 5 -CTGATGGTCTTCCTCAGACT-3 .
The identity of the purified PCR products (570 bp, OPN; 600 bp, OPG)
was verified by DNA sequencing and radiolabeled with random priming
using the ReadyProbe kit (Amersham Biosciences) and  [
32P]dCTP. 10  g of
RNA from FGF-treated or control RCS cells were used for Northern analysis.
In vitro kinase assays
cyclin E–associated kinase activity was measured as described previously
(Matsushime et al., 1994) In brief, precleared cell lysates were incubated
with 2  g anti-cyclin E antibody (sc-481, Santa Cruz Biotechnology, Inc.)
for 2 h at 4 C. Protein A Sepharose beads were added and incubated for
1 h at 4 C. The immunoprecipitates were washed and one-third analyzed
for kinase activity using 1  g Histone H1 substrate and 10  Ci  [
32P]ATP.
Western analysis
Cell lysates were prepared in RIPA buffer (10 mM Tris-HCl, pH 7.2, 150
mM NaCl, 5 mM EDTA, 0.1% SDS, 1% nedeoxycholate, and 1% Triton
X-100) and subjected to Western analysis as described previously (Laplan-
tine et al., 2002) using antibodies against pRb (G3–245; BD Biosciences),
p107 (C-18; Santa Cruz Biotechnology, Inc.), p130 (R27020; Transduction
Laboratories), p21(C-19; Santa Cruz Biotechnology, Inc.), or Cdk2 (sc-163;
Santa Cruz Biotechnology, Inc.).
In situ hybridization
Posterior limbs of P15 wild-type or 369/369 mice were fixed overnight in
4% PFA, embedded in paraffin, and sectioned at 7- m intervals. In situ hy-
bridization was performed as described previously (Wang et al., 1998) us-
ing antisense  [
35S]UTP-RNA probes. To prepare the probes, the OPN RT-
PCR product described earlier in Materials and methods was cloned into
the pGEM T-Easy vector (Promega). cDNAs of rat collagen X, Ihh, Id1 and
Id3, provided by Drs. H. Kronenberg (Massachusetts General Hospital,
Boston, MA), A. McMahon (Harvard University, Cambridge, MA), and R.
Benezra (Memorial Sloan-Kettering Cancer Center, New York, NY), were
each cloned into Bluescript. 20 ug of each plasmid DNA were linearized
and transcribed in the presence of  [
35S]UTP (PerkinElmer) using the ap-
propriate polymerase (T7, T3, or SP6; Promega). After hybridization and
washing, autoradiography was performed using Kodak NBT2 emulsion,
and the slides were exposed for 1–2 wk. The slides were counterstained
using hematoxylin. Hybridized probes were visualized using a dark field–
equipped microscope. Contiguous sections of those analyzed by in situ hy-
bridization were also triple stained with Alcian blue (Sigma-Aldrich), he-
matoxylin, and eosin.
Online supplemental material
Complete data sets for all of the microarray experiments described in this re-
port are available at http://www.jcb.org/cgi/content/full/jcb.200302075/DC1.
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